This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
OE05 is a phase 3 randomized treatment trial in esophageal cancer with an enrollment of 1300 participants. The registry identifies survival as the primary endpoint and lists cisplatin, epirubicin hydrochloride, fluorouracil, conventional surgery, and neoadjuvant therapy among the interventions.
| Feature | OE05 |
|---|---|
| Acronym | OE05 |
| ClinicalTrials.gov identifier | NCT00041262 |
| Phase | Phase 3 |
| Condition | Esophageal Cancer |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Enrollment | 1300 |
| Start date | 2004-11 |
| Study status | Unknown |
| Lead sponsor | Medical Research Council |
| Sponsor type | Other government |
2. Clinical Question
The registry describes OE05 as a randomized phase 3 treatment trial in patients with esophageal cancer. The central statistical question is whether the randomized treatment strategies being evaluated differ with respect to survival, the trial's registered primary endpoint.
Population
Patients with esophageal cancer.
Interventions
Cisplatin, epirubicin hydrochloride, fluorouracil, conventional surgery, and neoadjuvant therapy are listed in the registry.
Design
Randomized phase 3 treatment study with an enrollment of 1300.
Primary question
Does the randomized treatment strategy produce a difference in survival?
3. Trial Design
Randomization is the central design feature for a comparative treatment trial. If treatment assignment is randomized, baseline differences between groups arise from chance rather than from a deliberate selection process. This provides the foundation for interpreting a subsequent difference in survival as a treatment-group comparison, provided the trial's conduct and analysis preserve the benefits of randomization.
The phase 3 designation indicates the confirmatory stage of the clinical development program, but the phase label by itself does not specify the statistical test, estimand, allocation ratio, or follow-up schedule. Those details need to come from the registered design or statistical documentation when available.
4. Endpoints
| Endpoint | Registry definition | Statistical role |
|---|---|---|
| Survival | Survival | Registered primary endpoint |
The registry identifies survival as the sole registered primary endpoint. No additional primary-endpoint definition or time frame is reported in the information available from the registry record summarized here.
5. Planned Analysis
No formal statistical analyses are posted to ClinicalTrials.gov for the primary endpoint. The registry therefore provides the endpoint that is intended to be measured, but it does not provide a posted estimate, confidence interval, or p-value for survival.
How survival is typically analysed
For a randomized clinical trial in which survival is the primary endpoint, the usual analysis treats the time from a prespecified starting point until death as a time-to-event variable. Patients who have not experienced the event by the end of their available follow-up are typically right-censored.
The Kaplan-Meier method is commonly used to estimate the survival function over time. A comparison between randomized groups is often performed with a log-rank test, while a Cox proportional-hazards model can provide a hazard ratio and confidence interval.
Here, di is the number of events at time ti and ni is the number of individuals at risk immediately before that event time.
This approach is useful because it does not require every participant to have the event observed during the study. A participant who remains alive at the last available follow-up can contribute information up to that point and then be censored.
Hazard ratio as a comparative measure
A Cox model can summarize the relative event rate between treatment groups through a hazard ratio. Conceptually, an HR below 1 corresponds to a lower estimated instantaneous event rate in the treatment group relative to the comparator, while an HR above 1 corresponds to a higher estimated instantaneous event rate.
The hazard ratio for a treatment indicator is exp(β). It is a relative time-to-event measure rather than an absolute survival probability.
A hazard ratio should not automatically be interpreted as a relative risk over the entire follow-up period. The Cox interpretation concerns the modeled hazard, and its usual simple interpretation depends on the proportional-hazards assumption.
Absolute survival estimates
Kaplan-Meier survival probabilities at clinically relevant times can complement the hazard ratio by describing the estimated proportion surviving to a specified time point. Median survival is another commonly reported summary when the estimated survival curve falls to 0.50.
Neither a survival probability nor a median survival time is reported in the ClinicalTrials.gov information summarized here.
6. Statistical Methods Explained
Why is randomization important for survival analysis?
Randomization creates the treatment comparison before outcomes occur. In expectation, measured and unmeasured prognostic characteristics are distributed between randomized groups according to the randomization mechanism. This is what makes a subsequent between-group survival comparison fundamentally different from an observational comparison.
Why use Kaplan-Meier estimation?
Survival data are often incomplete because some participants remain alive when follow-up ends. Kaplan-Meier estimation incorporates these right-censored observations without treating them as deaths. The resulting curve estimates the probability of remaining event-free over time under the censoring assumptions.
What does a hazard ratio describe?
A hazard ratio compares the modeled instantaneous event rates between groups. An HR of 1 would correspond to equal hazards under the model; an HR below 1 would indicate a lower estimated hazard for the numerator group. It does not directly tell us the difference in median survival or the absolute number of additional survivors.
Why is the confidence interval important?
A point estimate alone does not describe statistical precision. A confidence interval gives a range of parameter values compatible with the data under the specified statistical framework. Wider intervals indicate greater uncertainty, while narrower intervals indicate greater precision. The width of the interval is affected by factors such as the amount of information and the number of observed events.
Why does censoring matter?
A censored participant is not treated as having experienced the event. Instead, that participant contributes information until the censoring time. Kaplan-Meier and Cox analyses rely on assumptions about the relationship between censoring and the event process. Informative censoring can undermine the interpretation of standard survival estimates.
What does a p-value tell us?
For a prespecified hypothesis test, a p-value measures how incompatible the observed data are with the null hypothesis under the test's statistical assumptions. It is not a measure of treatment effect size, clinical importance, or the probability that the null hypothesis is true. A complete interpretation therefore considers the effect estimate, its confidence interval, the endpoint definition, and the design of the trial together.
7. Interpreting Survival as a Primary Endpoint
Survival is inherently a longitudinal endpoint. Unlike a simple binary outcome measured once, each participant contributes a time component as well as an event indicator. The statistical analysis must therefore preserve the ordering and timing of events rather than reducing every participant to a single yes/no observation without regard to follow-up duration.
Time matters
Two patients with the same event status at the end of a study can contribute different amounts of information if their follow-up times differ.
Censoring matters
Patients without an observed event at the end of available follow-up are generally censored rather than counted as events.
Relative effects matter
A hazard ratio summarizes a relative difference in event rates over time under a fitted model.
Absolute effects matter
Survival probabilities at particular times can provide a more direct description of absolute prognosis than a relative hazard measure alone.
For a phase 3 randomized trial, these distinctions are especially important because the primary endpoint is generally intended to provide a rigorous comparison between treatment strategies. The statistical analysis should therefore be tied to the randomized treatment assignment and the prespecified endpoint definition.
8. Analysis Population and the Intention-to-Treat Principle
The registry information identifies the trial as randomized but does not report an analysis-population definition for the survival endpoint. In randomized trials, the intention-to-treat principle commonly means analysing participants according to the treatment group to which they were randomized, regardless of subsequent treatment changes.
This principle protects the comparison created by randomization. Excluding participants after randomization because they discontinue treatment, deviate from the protocol, or receive another intervention can alter the composition of the groups and introduce selection effects.
9. Hazard Ratios, Absolute Effects, and Clinical Interpretation
A hazard ratio provides a relative comparison of event rates over time. It does not by itself reveal the absolute survival probability at a clinically meaningful time point.
A survival probability describes the estimated proportion of participants who remain alive at a specified time. Absolute measures can make the magnitude of a treatment difference easier to understand in terms of patient outcomes.
The median survival time is the time at which the estimated survival function reaches 0.50. If the curve does not reach 0.50 during the available follow-up, the median cannot be estimated from that follow-up period.
These measures are complementary rather than interchangeable. A hazard ratio compresses information from the event-time distribution into a relative effect measure, while a Kaplan-Meier curve retains more of the temporal structure. Time-specific survival estimates then provide an absolute perspective.
10. Proportional-Hazards Assumption
When a Cox proportional-hazards model is used, the conventional hazard-ratio interpretation assumes that the relative hazard between groups is reasonably stable over time. If hazards cross or the treatment effect changes substantially during follow-up, a single hazard ratio can obscure important features of the survival experience.
The ClinicalTrials.gov record summarized here does not report a proportional-hazards assessment or a specific alternative survival estimand. Consequently, no such trial-specific conclusion can be drawn from the registry record.
11. Interim Analysis, Multiplicity, and Other Design Features
The registry information summarized here does not report an interim-analysis plan, alpha-spending strategy, multiplicity procedure, non-inferiority margin, crossover plan, missing-data or imputation strategy, stratification factors, or Bayesian analysis for OE05.
These design features can materially affect the interpretation of a clinical-trial result when they are part of the prespecified statistical plan. For example, repeated interim efficacy looks require appropriate type I error control, while multiple confirmatory endpoints may require an explicit multiplicity strategy.
| Statistical feature | Registry information summarized here |
|---|---|
| Randomization | Reported |
| Primary endpoint | Survival |
| Interim analysis | Not reported |
| Alpha spending | Not reported |
| Multiplicity adjustment | Not reported |
| Non-inferiority margin | Not reported |
| Crossover | Not reported |
| Missing-data / imputation method | Not reported |
| Stratification factors | Not reported |
| Bayesian methods | Not reported |
The absence of these details in the registry record should not be interpreted as evidence that the underlying trial protocol lacked such procedures. It means that the summarized registry information does not report them.
12. Limitations
- No posted statistical results: the registry does not contain a posted statistical analysis for the primary survival endpoint, so no survival estimate, hazard ratio, confidence interval, or p-value is reported here.
- Limited endpoint detail: the registered primary endpoint is simply described as “Survival,” without a more detailed event definition or time frame in the information summarized here.
- Allocation detail: the registry identifies the study as randomized but does not provide treatment-group sample sizes or an allocation ratio in the information available here.
- Intervention structure: multiple drugs and procedures are listed, but the summarized registry information does not establish the exact combination or assignment structure for each treatment group.
- Analysis details: the registry information does not specify the statistical model, test procedure, censoring rules, stratification factors, or analysis population used for the primary endpoint.
- Safety information: no arm-specific serious-adverse-event results are included in the registry information summarized here.
- Follow-up information: the registry information does not provide survival follow-up duration, event counts, median survival, or time-specific survival estimates.
13. Why This Trial Matters Statistically
OE05 provides a useful framework for understanding how a randomized phase 3 oncology trial can be organized around a time-to-event endpoint. Even without posted numerical results, the registry structure illustrates the distinction between a trial's design, its endpoint, and the statistical analysis required to estimate the treatment effect.
| Concept | How it appears in OE05 |
|---|---|
| Randomization | The trial is registered as randomized. |
| Phase 3 design | The trial is registered as phase 3. |
| Time-to-event endpoint | Survival is the registered primary endpoint. |
| Censoring | Relevant to the usual statistical treatment of survival data. |
| Kaplan-Meier estimation | A standard method for estimating survival over time. |
| Log-rank testing | A standard method for comparing survival distributions between randomized groups. |
| Cox regression | A standard model for estimating a hazard ratio for a time-to-event endpoint. |
| Confidence intervals | Used to express uncertainty around estimated treatment effects. |
| Intention-to-treat | A common analysis principle for preserving randomized treatment comparisons. |
14. From Registry Endpoint to Statistical Estimand
The word “survival” describes the clinical outcome, but a statistical analysis requires a more precise estimand. A useful estimand specifies what population is being studied, what treatment comparison is being made, what outcome is measured, how intercurrent events are handled, and the summary measure used to quantify the difference.
This framework helps prevent a common statistical mistake: treating the name of an endpoint as if it already determines the complete analysis. “Survival” does not by itself specify whether the principal comparison should be a hazard ratio, a restricted mean survival time, a fixed-time survival difference, or another measure. The prespecified analysis plan determines that choice.
15. What Would a Complete Survival Analysis Contain?
For readers learning clinical-trial statistics, it is useful to separate the elements of a complete survival report.
| Component | Purpose |
|---|---|
| Number randomized | Defines the size of the randomized comparison. |
| Number of events | Describes the amount of observed event information. |
| Follow-up duration | Provides temporal context for the analysis. |
| Kaplan-Meier curve | Shows the estimated survival experience over time. |
| Median survival | Summarizes the time at which estimated survival reaches 50%, when estimable. |
| Fixed-time survival | Provides an absolute survival estimate at a specified time. |
| Hazard ratio | Provides a relative time-to-event effect estimate under the fitted model. |
| Confidence interval | Quantifies uncertainty around the effect estimate. |
| Hypothesis test | Assesses the data relative to a prespecified null hypothesis. |
| Analysis population | Defines which randomized or treated participants contribute to the analysis. |
The ClinicalTrials.gov record for OE05 identifies the primary endpoint but does not provide these numerical survival-analysis results in the posted statistical analyses summarized here. The appropriate interpretation is therefore a design-and-methodology interpretation rather than an outcome-effect interpretation.
16. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
OE05 is a randomized phase 3 treatment trial with survival designated as its primary endpoint. A complete analysis would compare the survival experience generated by the randomized treatment strategies using an appropriate time-to-event framework.
Clinical interpretation
The clinical outcome of interest is survival in patients with esophageal cancer. The registry identifies the treatment context and primary endpoint but does not provide a posted numerical survival comparison.
Keeping these two levels separate is important. Statistical methodology determines how the observed survival data should be summarized and compared. Clinical interpretation then considers the resulting estimates in the context of the disease, treatment strategies, follow-up, uncertainty, and other relevant evidence.
17. Reading a Kaplan-Meier Curve
If a Kaplan-Meier curve were available, the vertical axis would represent estimated survival probability and the horizontal axis would represent time from the prespecified time origin. Each downward step would correspond to one or more observed events, while censored observations would generally be indicated separately.
The curve should be interpreted together with the number at risk and censoring information, especially toward the end of follow-up where relatively few participants may remain under observation.
The shape of a survival curve also contains information that a single hazard ratio does not. Curves may separate early or late, remain separated throughout follow-up, or approach one another. A single summary statistic can therefore be useful while still failing to describe every clinically relevant feature of the time-to-event distributions.
18. Statistical Interpretation of a Future Effect Estimate
If a formal analysis reports an estimated hazard ratio, the estimate should be read in conjunction with its confidence interval and the statistical model that produced it.
A hazard ratio compares the estimated instantaneous event rates between the randomized groups under the fitted survival model.
It is not the percentage of patients who benefit, the percentage difference in survival probability, or the probability that one treatment is superior.
The confidence interval expresses uncertainty around the estimated model parameter under the specified statistical framework. It does not describe the range of individual patient outcomes.
A p-value addresses compatibility with a specified null hypothesis under the assumptions of the test. It does not quantify the magnitude or clinical importance of the treatment effect.
This distinction is fundamental in clinical-trial reporting. Statistical evidence, effect magnitude, precision, and clinical relevance are related but different dimensions of an analysis.
19. Limitations of Registry-Based Statistical Interpretation
A registry is primarily a structured record of a clinical study rather than a complete statistical report. Its value for statistical education is substantial, but endpoint names and high-level design descriptors do not substitute for the full statistical analysis plan or the complete results report.
- Endpoint specification: a broad endpoint label may require additional operational definitions before a precise estimand can be identified.
- Event information: survival analysis depends heavily on the number and timing of events, which are not reported here.
- Censoring: without censoring rules and follow-up information, the details of a Kaplan-Meier analysis cannot be established.
- Model specification: the registry information does not identify a particular Cox model, log-rank procedure, or alternative survival method.
- Multiplicity: no posted information establishes whether multiple statistical hypotheses required formal error control.
- Analysis populations: the registry information does not specify whether the primary survival analysis used all randomized participants or another prespecified population.
20. Sources
- ClinicalTrials.gov: OE05 (NCT00041262).
- PubMed: PubMed record associated with the OE05 study.
Continue through the Clinical Biostats knowledge graph
Explore additional Clinical Biostats resources on clinical-trial design, survival analysis, and statistical methodology.
21. Record Summary
OE05 is a randomized phase 3 treatment trial involving 1300 participants with esophageal cancer. The registry identifies survival as its primary endpoint and lists cisplatin, epirubicin hydrochloride, fluorouracil, conventional surgery, and neoadjuvant therapy among the interventions. From a statistical perspective, survival is a time-to-event endpoint for which Kaplan-Meier estimation, log-rank comparison, and Cox proportional-hazards modeling are commonly relevant approaches.
The most important statistical lesson is that the endpoint name alone does not constitute a complete analysis. A rigorous interpretation requires the treatment assignment structure, event definition, time origin, censoring rules, analysis population, event count, follow-up duration, effect estimate, confidence interval, and prespecified hypothesis-testing framework. Those details determine how the survival comparison should ultimately be interpreted.